Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037931 · ClinicalTrials.gov registry record · Phase 3
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,065
- Enrollment target
NCT03037931 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 3,065 participants.
The verdict
NCT03037931, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,065 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
Interventions
- DRUG Placebo
- DRUG Ferric Carboxymaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,065 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03037931
The ClinicalTrials.gov registry entry for NCT03037931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,065 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03037931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03037931 about?
NCT03037931 is a clinical study titled "Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study". The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
What is the current status of trial NCT03037931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,065 participants. The study started on 2017-03-15. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT03037931?
The interventions under investigation include: Placebo (DRUG), Ferric Carboxymaltose (DRUG).
Who is sponsoring clinical trial NCT03037931?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.